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Impact of angiotensin-converting enzyme inhibition
on platelet tissue factor expression in stroke-prone rats
Marta Brambillaa,!, Paolo Gelosaa,!, Laura Rossettia,!, Laura Castiglionib, Chiara Zaraa,
Paola Canzanoa, Elena Tremolia,b, Luigi Sironia,b, and Marina Cameraa,b
Objective: Hypertension is a well known risk factor for
thrombotic events such as myocardial infarction and
stroke. Platelets express tissue factor (TF), the key activator
of blood coagulation and thrombus formation. The
number of TF-positive platelets increases in pathological
conditions characterized by thrombotic complications but
whether this occurs in hypertension is unknown. Here we
investigated whether platelet TF expression is increased in
a hypertensive status through a mechanism acting on
megakaryocytes; the phenomenon could be modulated by
antihypertensive drug as captopril; angiotensin (AngII)
influences platelet TF expression.
Methods: Spontaneously hypertensive stroke prone
(SHRSP) rats received standard diet (StD) or a Japanese
high-salt permissive diet (JpD). After 3 weeks, JpD animals
were randomized to receive captopril or vehicle.
Normotensive Wistar Kyoto (WKY) rats were used as
controls. Cell-associated TF expression and activity were
analyzed by flow cytometry and calibrated automated
thrombogram, respectively.
Results: Hypertensive StD-SHRSP showed an increased
number of TF-positive platelets compared with
normotensive WKY. After JpD administration, SHRSP
developed severe hypertension and renal damage; the
number of TF-positive megakaryocytes significantly
increased compared with StD-SHRSP resulting in a higher
number of TF-positive platelets with a faster kinetic of
thrombin generation. These effects were reverted by
captopril. Ex-vivo stimulation of platelets, isolated from
normotensive WKY and from healthy individuals, with
AngII induced a concentration-dependent increase of
surface-associated TF expression.
Conclusion: The current study shows for the first time
that in hypertension the number of TF-positive
megakaryocytes increases thus releasing in the circulation
more platelets carrying a functionally active TF. AngII
stimulates platelets to express TF.
Keywords: angiotensin II, antihypertensive drug, blood
pressure, platelets, stroke-prone rats, tissue factor
Abbreviations: ACE, angiotensin-converting enzyme;
AngII, angiotensin; JpD, Japanese high-salt permissive diet;
SHRSP, spontaneously hypertensive stroke prone rats; StD,
standard diet; TF, tissue factor; Val5AngII, selective AT1
agonist; WKY, Wistar Kyoto rats
INTRODUCTION
Hypertension is a well known risk factor for cardio-vascular diseases [1]. Indeed it has been linkedwith a prothrombotic state characterized by plate-
let activation and increased levels of circulating as well as
monocyte-associated tissue factor (TF) expression [2].
TF is the main activator of the blood coagulation cas-
cade, and it has been shown by us and others to be
expressed also by human platelets, which transfer it on
their cell surface upon activation [3–5]. More recently, we
have provided evidence that TF behaves as an endoge-
nously synthesized protein that characterizes megakaryo-
cyte maturation and that it is transferred to a subset of newly
released platelets. Platelet TF is functionally active and able
to trigger thrombin generation, thus contributing to the
global platelet hemostatic capacity [6].
The number of TF-positive platelets increases in patho-
logical conditions such as in patients with cancer, with
polycythemia vera and essential thrombocythemia, and
with acute coronary syndrome [7–9]. Among the cardio-
vascular risk factors, diabetes has been shown to affect
platelet TF expression both in human and in rat platelets
[10,11]. Of interest, in a recent study carried out to elucidate
the hypoxia-induced prothrombotic phenotype, the prote-
omic analysis of platelets isolated from rats exposed to
hypoxic stimulus showed that TF was one of the differen-
tially expressed proteins (increased expression compared
with controls), thus potentially contributing to the throm-
botic risk associated with a hypoxic environment [12].
Whether platelet TF expression is affected in hyperten-
sion is so far a missing information. Thus, to address this
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issue, we took advantage from the spontaneously hyper-
tensive stroke prone (SHRSP) rats, a strain which, among
the available hypertensive rat models, most recapitulates
the evolution of human essential hypertension, gradually
developing renal injury and ultimately also stroke [13,14]. In
these animals, we investigated, bywhole blood flow cytom-
etry, whether a condition of hypertension and also organ
damage affect platelet TF expression and whether a mech-
anism acting on megakaryocytes at the bone marrow level
could be involved.
In the setting of a severe hypertensive status, character-
ized by a marked organ damage, we also evaluated the
effect of captopril on platelet and megakaryocyte TF
expression.
Finally, as angiotensin (AngII), which is significantly
increased in severe hypertensive SHRSP rats [15,16], indu-
ces TF expression in monocytes, in endothelial cells and in
smooth muscle cells [17–19] we evaluated, by means of ex-
vivo experiments, its effect on platelet TF expression.
METHODS
Experimental plan
The procedures concerning animal care and euthanasia
were carried out in accordance with national and interna-
tional laws and policies, and authorized by the Ministry of
Health – Committee of Universita` degli Studi di Milano
(approval number 12/12-30012012).
The flowchart of this study is described in Fig. 1. In
details, 7-week-old male SHRSP (n¼ 33, Charles River,
Wilmington, Massachusetts, USA) were randomly divided
to be fed with a standard diet (StD; n¼ 10) or with a
Japanese high-salt permissive diet (JpD; n¼ 23) containing
18.7% proteins, 0.63% potassium and 0.37% sodium
(Laboratorio Dottori Piccioni, Gessate, Milan, Italy) and
received 1% NaCl in drinking water [14]. After 3 weeks,
when a marked increase of blood pressure (BP) levels
together with the onset of renal damage was induced by
JpD, consistent with our previous study [14], JpD-SHRSP
rats were randomized to receive or not captopril (50mg/kg
per day; Sigma-Aldrich, St Louis, Missouri, USA) dissolved
in drinking water (JpD-cap; n¼ 10 and JpD; n¼ 13). To be
sure of completeness of the administration, captopril was
dissolved in 5ml of drinking water and administered to
each rat. After the ingestion of the full dose of the drug,
drinking water and 1% NaCl was available to each animal
ad libitum.
Seven-week-old male Wistar Kyoto (WKY; n¼ 15) rats
were chosen as normotensive control animals and ran-
domly assigned to be fed with StD-WKY (n¼ 10) or JpD-
WKY (n¼ 5).
Systolic arterial BP measurements were performed at
baseline (week 0) and after 3, 4 and 8 weeks, in conscious
rats using a tail-cuff plethysmography (BP-2000; Visitech
Systems, Apex, North Carolina, USA). Rats were condi-
tioned to the restraint and the warming chamber for 10–
20min/day for at least 2 days prior to measurements. After
this training period, BP was measured. Following the same
time schedule, the animals were housed in individual cages
for 24 h for urine collection and proteinuria evaluation.
At week 3, a group of JpD-SHRSP (n¼ 3) was sacrificed
and kidney was processed for histological analysis as
control of the illness severity stage before captopril admin-
istration. As the aim of the study was to characterize the
platelet activation in hypertensive state, avoiding that due
to a stroke event [20], all the other (n¼ 10) severe hyper-
tensive SHRSP animals (JpD) were sacrificed after 4 weeks
from the beginning of the study. Within this timing, based
FIGURE 1 Outline of the experimental protocol. Spontaneously hypertensive stroke prone (n¼33) and Wistar Kyoto (n¼15) rats were randomly divided to be fed with a
standard diet or with a Japanese high-salt permissive diet. Three weeks after the beginning of the study, Japanese high-salt permissive diet-spontaneously hypertensive
stroke prone rats were randomized to receive or not captopril (50mg/kg per day) dissolved in drinking water (Japanese high-salt permissive diet-cap, n¼10; Japanese
high-salt permissive diet, n¼13). At the time of randomization, a group of Japanese high-salt permissive diet-spontaneously hypertensive stroke prone (n¼3) was
sacrificed and kidney was processed for histological analysis. To avoid the onset of stroke events, 4 weeks from the beginning of the study all the other Japanese high-salt
permissive diet-spontaneously hypertensive stroke prone were sacrificed together with Japanese high-salt permissive diet-Wistar Kyoto and half of the number of standard
diet-Wistar Kyoto, Japanese high-salt permissive diet-cap and standard diet-spontaneously hypertensive stroke prone rats for data comparison. The remaining animals were
sacrificed after 8 weeks.
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on our previous experience [14], no stroke event occurred,
as confirmed by brain T2-weighted MRI analysis [21] per-
formed on all animals before sacrifice. JpD-WKY and half of
the number of StD-WKY, of JpD-cap and StD-SHRSP rats
were sacrificed together with the JpD-SHRSP animals for
data comparison, whereas the remaining animals were
sacrificed after 8 weeks.
Blood and bone marrow collection
Four and 8 weeks from the beginning of the study, blood
was drawn from the tail vein with a 23-ga needle into citrate
(1/10 volume of 0.129mol/l sodium citrate) and corn tryp-
sin inhibitor (50mg/ml) – containing tubes. Blood cell
counts were determined with the Sysmex XT-2000iV Hema-
tology Analyzer (Dasit, Cornaredo, Milan, Italy). For platelet
isolation, whole blood was diluted (five-fold) in saline
solution (0.9-g/l NaCl) and centrifuged at 75$ g for
15min at room temperature (RT) with brake off. Platelet-
rich plasma (PRP) was then centrifuged at 10 000$ g for
5min and platelet pellets stored at %80 8C until used.
Mononuclear leukocytes were separated by centrifugation
of platelet depleted blood on a Ficoll-Paque density gradi-
ent (GE Healthcare Life Sciences, Chicago, Illinois, USA),
according to manufacturer’s instructions, and stored at
%80 8C until used.
At sacrifice, femurs from four rats for each experimental
group were isolated to collect megakaryocytes. Briefly,
bone marrow was flushed into PBS containing 1/10 volume
of 0.129-mol/l sodium citrate and 1-mmol/l EDTA and
single-cell suspensions used for flow cytometry analysis.
Histological analysis
Paraffinized slices (5mm) of renal tissue fixed in 10%
formalin (Merck, Germany) were used for staining with
hematoxylin/eosin. Tubular atrophy and luminal cast for-
mations were assigned to a separate scores ranging from 0
to 3 (absent, mild, moderate and severe changes), and the
scores were combined to obtain a mean tubular damage
score, as previously described [22].
At least 1000 tubules were examined from each animal
(n¼ 3 rats for JpD-SHRSP at 3 weeks; n¼ 5 rats for all other
groups).
Flow cytometry
Tissue factor expression was analyzed by flow cytometry on
1%paraformaldehyde fixedwholebloodorbonemarrow.For
intracellular staining, cellswere permeabilized for 10minwith
a 0.1% Triton X 100-PBS solution. Surface and intracellular
antigen staining were performed as follows: 2.5ml of samples
were incubated for 15min, in the dark, at RT, with saturating
concentration of centrifuged (17000$ g, 5min, 4 8C) rabbit
anti-TF antibody (1.5mg/sample, Abcam, Cambridge, UK).
Samples were centrifuged at 1500$ g for 5min and incubated
with goat anti-rabbit Alexa Fluor 633 labeled IgG (1 : 200,
Thermo Fisher, Waltham, Massachusetts, USA). After a wash-
ing step, phycoerythrin-conjugated anti-CD61 (500ng/
sample, Abcam) and fluorescein-isothiocyanate conjugated
anti-CD45 (100ng/sample, Abcam) antibodies were added.
Fluorochrome-conjugated isotype or Alexa Fluor 633-
labeled IgG controls were used in all the experiments to
quantify the background labeling. A total of 10 000 CD61-
positive or 5000 CD45-positive events per sample were
acquired on a BD FACSCalibur. Cytometer performances
were checked by daily running BD CompBeads. Data are
reported as percentage of cells positive for the analyzed
antigens or as mean fluorescence intensity. All the data
were analyzed with DIVA Software (BD Biosciences, San
Jose´, California, USA).
Imaging flow cytometry
Imaging flow cytometry was performed on ImageStreamX
MarkII (Amnis, Seattle, Washington, USA). Bone marrow
fixed cells were stained with phycoerythrin-conjugated
anti-CD61 (500 ng/sample, Abcam), Alexa488 labeled
anti-TF antibody (1.5mg/sample, Abcam) and with DRAQ5
(5mmol/l, Abcam), a fluorescent DNA dye used for
nuclei identification.
Events were acquired with the 20$ objective, at low flow
rate/high sensitivity. Data analysis was performed with
IDEAS software (version 6.1; Amnis). Megakaryocytes were
analyzed by gating on CD61-positive and focused events,
with an area higher than 1000mm2. Cell aggregates were
excluded from analysis by selecting only the single-cell
population defined as events with an aspect ratio (minor
axis/major axis of a selected event) higher than 0.6. Images
were compensated based on a matrix generated by single-
stained samples acquired with identical laser settings in the
absence of brightfield illumination.
Thrombin generation assay
The thrombin generation capacity of platelets was analyzed
on cell lysates. Cells, isolated as described above, were
solubilized with 15-mmol/l octyl-b-D-glycopyranoside at
37 8C for 15min, sonicated for 1min, diluted with 25-
mmol/l HEPES–saline buffer and tested for their capacity
to promote thrombin generation using the calibrated auto-
mated thrombogram (CAT) assay. An amount of 40ml of
platelet lysate (containing 4mg of proteins) was incubated
for 10min with 40ml of platelet-free normal pooled plasma
(Pool Norm; Stago, Maastricht, The Netherlands) in round-
bottom 96-well microtiter plates (Immulon 2HB). Thrombin
generation was triggered by the addition of 20ml of CaCl2/
fluorogenic substrate mixture (FluCa Kit; Stago) and fluo-
rescence was read for 60min in a Fluoroskan Ascent reader
(Thermo Labsystems, Philadelphia, Pennsylvania, USA)
equipped with a 390/460 filter set. Samples devoid of cell
lysates were run to set the background level of thrombin
generated by the assay. To this aim, 40ml of platelet-free
normal pooled plasma (Pool Norm; Stago) were incubated
with 40ml of octyl-b-D-glycopyranoside/HEPES–saline
buffer. To assess the TF-dependent contribution to throm-
bin generation, the CAT assay was performed after prein-
cubation of the samples with a neutralizing anti-TF
antibody (100mg/ml, cat 4501; Sekisui Diagnostics, Lex-
ington, Massachusetts, USA). To correct for inner filter
effects and substrate consumption, all thrombin generation
measurements were calibrated against the fluorescence
curve obtained after the addition of fixed amount of throm-
bin-a2-macroglobulin complex (Thrombin Calibrator;
Stago). Thrombin generation curves were analyzed by
dedicated software (Thrombinoscope BV). Lag time
Platelet tissue factor in hypertension
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(min), peak height (nmol/l thrombin) and the velocity
index (nmol/l thrombin/min) were used as main parame-
ters describing thrombin generation.
Ex-vivo stimulation of rat and human platelets
with angiotensin
For ex-vivo studies, blood from normotensive WKY rats
(n¼ 6) was drawn from the tail vein and PRP was prepared
as described above. A total of 1$ 106 platelets were stimu-
lated with collagen (1 and 4mg/ml) or selective AT1 agonist
(Val5AngII) (1, 10 and 100 nmol/l, Santa Cruz, Dallas,
Texas, USA) [23], for 5min, at 37 8C, under stirring condi-
tion. Preincubation with valsartan (500 nmol/l, Sigma-
Aldrich), an AT1 antagonist, was carried out for 2.5min
before cell stimulation. Platelet TF expression was analyzed
by flow cytometry as reported above.
For experiments on human platelets, venous blood was
collected from healthy individuals (n¼ 3) who did not take
antiplatelet drugs within 10 days before blood donation and
who gave their informed consent to participate in the study.
After the first 4ml were discarded, whole blood was drawn
with a 19-ga needle without venous stasis into citrate-
containing tubes (1/10 volume of 0.129mol/l sodium cit-
rate, Vacutainer; Becton Dickinson, Franklin Lakes, New
Jersey, USA). PRP was prepared by whole blood centrifu-
gation at 100$ g for 10min, with brake off, and platelet
count was determined with the Sysmex XS-1000i Hematol-
ogy Analyzer (Dasit). Platelets (1$ 106) were stimulated
with increasing concentration of AngII (100 pmol/l–
100 nmol/l, Sigma-Aldrich), for 5min, at 37 8C, under stir-
ring condition, in the presence of saturating concentrations
of MoAb against human TF (cat 4507CJ, Sekisui) and human
GpIIb (CD41; Beckman Coulter, Brea, California, USA).
Platelet surface TF expression was analyzed by flow cytom-
etry as previously described [9].
Statistical analysis
Data were expressed as the mean& SD. General linear
models (GLM) were applied to evaluate, on all dependent
variables, the effect of rat strain and diet and their interac-
tion. Post-hoc tests, with Bonferroni correction, were per-
formed to assess differences between specific combinations
of strain and diet. Another GLM was applied to evaluate the
effect of captopril in SHRSP rats. The effect of captopril
treatment was analyzed as a trend according to treatment
duration and post-hoc tests with Bonferroni correction
were performed between specific treatments (no captopril,
1-week treatment and 5-week treatment).
In ex-vivo experiments, analysis of variance with post-
hoc tests was used to compare independent groups. Anal-
yses were performed using SAS V9.4 statistical package
(SAS Institute, Cary, North Carolina, USA). A P value less
than 0.05 was considered statistically significant.
RESULTS
Effect of Japanese diet and captopril treatment
on SBP and renal organ damage
The mean values of the systolic arterial BP as well as the
24-h proteinuria levels of the animals included in the study
are summarized in Tables 1 and 2, respectively.
For all the variables, the effect of rat strain and diet as
well as their interactions are reported in the Online Sup-
plementary Table S1, http://links.lww.com/HJH/A906.
At the beginning of the study, BP of SHRSP rats fed with
the StDwas already significantly higher comparedwith StD-
WKY (166& 14 vs. 143& 7mmHg, respectively; P¼ 0.003).
It slightly increased after 3 weeks remaining unchanged
until the end of the study. The urinary protein excretion in
this animal group was constant throughout the study period
and comparable to that of StD-WKY, indicating that no
renal damage occurred in this hypertensive strain fed with a
StD, as also confirmed by the histological analysis of the
kidney (Fig. S1, http://links.lww.com/HJH/A906).
Conversely, administration of high-salt diet (JpD) for 3
weeks induced severe hypertension in SHRSP rats with a
concomitant significant increase in urinary protein excre-
tion. At week 4, no further change in BP was recorded,
whereas a'17-fold higher proteinuria level compared with
StD-SHRSP rats was measured. The establishment of the
severe renal damage in JpD-SHRSP rats was confirmed by
the histology of the kidney (Fig. S1, http://links.lww.com/
HJH/A906). At week 3, JpD-SHRSP rats showed a mild
vascular alterations characterized by the presence of few
atrophic tubules. One week later, the renal tissue structure
worsened and severe tubular damage and luminal cast
formation significantly increased.
Of note, JpD did not induce significant variation of BP
and of proteinuria levels in WKY animals. Indeed, the
kidney of JpD-WKY animals showed no relevant
histological abnormalities.
Captopril administered for 1 week to JpD-SHRSP slightly
affected BP, which was significantly reduced only after
5 weeks of treatment (Table 1). Conversely, much more
TABLE 1. Rat systolic arterial blood pressure values
Pressure (mmHg) Week 3 Week 4 Week 8
StD-SHRSP 180&14! 183&21 184&9
JpD-SHRSP 229&19!! 233&17!!! ND
JpD-cap ND 216&20 202&16!!!!
StD-WKY 144&9 ND ND
JpD-WKY 153&9 ND ND
Data are mean (mmHg)& SD. General linear models were applied for statistical analysis.
JpD, Japanese high-salt permissive diet; ND, not determined; SHRSP, spontaneously
hypertensive stroke prone; StD, standard diet; WKY, Wistar Kyoto.
!P¼ 0.0001 StD-SHRSP vs. StD-WKY.
!!P< 0.0001 StD-SHRSP vs. JpD-SHRSP.
!!!P¼0.001 StD-SHRSP vs. JpD-SHRSP.
!!!!P<0.05 JpD-cap vs. JpD-SHRSP by post-hoc test adjusted by Bonferroni correction.
TABLE 2. Levels of 24-h proteinuria
Proteinuria (mg/day) Week 3 Week 4 Week 8
StD-SHRSP 14.1&8.5 14.2&7.9 14.5&3.8
JpD-SHRSP 81.4&82.5! 240&83!! ND
JpD-cap ND 56.6&26.7!!! 28.4&11.7
StD-WKY 13.9&1.6 14.1&6 15.9&6.4
JpD-WKY 13.0&2.8 15.8&4.5 ND
Data are mean (mg/day)& SD. General linear models were applied for statistical analysis.
JpD, Japanese high-salt permissive diet; ND, not determined; SHRSP, spontaneously
hypertensive stroke prone; StD, standard diet; WKY, Wistar Kyoto.
!P¼ 0.0007 StD-SHRSP vs. JpD-SHRSP (week 3).
!!P< 0.0001 StD-SHRSP vs. JpD-SHRSP (week 4).
!!!P<0.0001 JpD-cap vs. JpD-SHRSP (week 4) by post-hoc test with Bonferroni
correction.
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pronounced was the effect of the drug on the organ
damage – that was prevented (Fig. S1, http://link-
s.lww.com/HJH/A906) – and in turn on the proteinuria
that, in 5-week treatment, reverted to a normal range (Table
2).
Platelet tissue factor expression
To evaluate the relationship between hypertension and
platelet-associated TF, cell-surface and intracellular TF lev-
els were analyzed by whole blood flow cytometry in SHRSP
rats as well as in WKY control animals.
The number of platelets expressing TF, both on the cell
surface as well as in the cytoplasm, was two-fold higher in
hypertensive StD-SHRSP compared with normotensive StD-
WKY animals (Fig. 2a and b). Of note, when the samples
were analyzed for intracellular expression of TF, about
three-fold higher amount of TF-positive platelets was
detected compared with that measured with the cell-
surface staining.
The percentage of circulating TF-positive platelets fur-
ther doubled in JpD-SHRSP animals compared with StD-
SHRSP, with the onset of a marked organ damage due to the
JpD treatment (week 4). Prevention of renal damage by
captopril administration reduced the number of TF-positive
platelets (week 4), which returned to the StD level after 5
weeks of treatment (Fig. 2a and b).
Flow cytometry analysis of leukocyte TF expression
indicated that, in this experimental setting, unlike what
was observed for platelets, hypertension did not affect
the number of TF-positive monocytes (Fig. 3a) and gran-
ulocytes (Fig. 3b), even in the presence of severe organ
damage.
Platelet thrombin generation capacity
The CAT assay was performed to assess the thrombin
formation capacity of platelets. Platelets from hypertensive
StD-SHRSP rats generated thrombin in a faster kinetic
rate compared with normotensive StD-WKY (lag time:
16.5& 3.1 vs. 22.2& 2.1min, respectively; P¼ 0.001;
Fig. S2, http://links.lww.com/HJH/A906), paralleling the
FIGURE 2 Analysis of tissue factor expression in platelets by flow cytometry. Cell-
surface (a) and intracellular (b) tissue factor expression was analyzed in platelets,
identified as CD61-positive events, of Wistar Kyoto and spontaneously hyperten-
sive stroke prone animals. As no differences were detected within standard diet-
Wistar Kyoto and standard diet-spontaneously hypertensive stroke prone animals
after 4 and 8 weeks, data were pooled. Data are shown as percentage of tissue
factor-positive events. Lines in the dot plots are mean& SD. General linear models
were applied for statistical analysis. Reported P values were obtained by post-hoc
tests with Bonferroni correction.
FIGURE 3 Analysis of cell-surface tissue factor expression in monocytes and gran-
ulocytes by flow cytometry. Cell-surface tissue factor expression was analyzed in
monocytes (a) and granulocytes (b) of a subgroup of Wistar Kyoto and spontane-
ously hypertensive stroke prone rats. Cells were identified according to their physi-
cal properties (high forward and side scatter) and to CD45 expression. Lines in the
dot plots are mean& SD. No significant differences between groups were
observed. General linear models were applied for statistical analysis, followed by
post-hoc tests with Bonferroni correction.
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higher percentage of TF-positive platelets circulating in
SHRSP animals. The thrombin formation was further faster
in JpD-SHRSP compared with StD-SHRSP rats (lag time:
11.4& 1.7 vs. 16.5& 3.1min, P¼ 0.041 and velocity index:
62.2& 23.0 vs. 40.7& 14.2mmol/l per min, P¼ 0.05, respec-
tively; Fig. 4a and b), and this feature was accompanied by a
trend toward a greater amount of thrombin (peak height:
194.3& 30.0 vs. 146.0& 24.4 nmol/l; P¼ 0.09, Fig. 4c). Of
interest, treatment with captopril for 5 weeks was able to
restore the thrombin generation capacity of platelets to the
values observed in StD-SHRSP animals (Fig. 4a–c), in
agreement with the effect on TF expression assessed by
flow cytometry.
To investigate the direct contribution of platelet TF to the
thrombin generation, the assay was performed after pre-
incubation of cell lysates from StD-SHRSP and JpD-SHRSP
rats with a neutralizing anti-TF antibody. In this experimen-
tal condition, the onset of thrombin generation was delayed
FIGURE 4 Assessment of thrombin generation capacity of platelets. Platelet prothrombotic potential was analyzed by thrombin generation assay (calibrated automated
thrombogram) in platelet lysates. Lag time [time needed to start thrombin formation (a)], velocity index [velocity of thrombin formation (b)] and peak height [maximum
concentration of generated thrombin (c)] were used as main parameters describing thrombin generation. Representative curves (gray lines) from platelet lysates of standard
diet (d) and hypertensive (e) animal are reported. Curves generated in the absence of cell lysates (dashed lines) are shown for comparison. Thrombin generation analyzed
in the presence of neutralizing antitissue factor antibody (100mg/ml AbTF, black lines) is reported. Data in the histograms are mean& SD. General linear models were
applied for statistical analysis. P values were obtained by post-hoc tests with Bonferroni correction.
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becoming similar to that measured in the absence of platelet
lysates (i.e. plasma alone; Fig. 4d and e). As expected, the
delay in thrombin formation was greater in platelets from
JpD-fed animals, reflecting the higher number of TF-posi-
tive platelets compared with that of StD-fed rats.
Megakaryocyte tissue factor expression
Bone marrow megakaryocytes were analyzed at sacrifice to
verify if the increased number of TF-positive platelets
observed in hypertensive SHRSP animals was associated
with an increase in TF expression in the platelet progenitor
cells. Megakaryocytes were carefully identified taking
advantage from imaging flow cytometry according to their
physical properties (high forward and side scatter) and high
CD61 expression (Fig. S3, http://links.lww.com/HJH/A906
and Fig. 5a). The selected population had a mean cell
diameter of 39.2& 6.7mm and showed different degree
of polyploidy as assessed by nuclear staining with DRAQ5
(data not shown). Analysis of cell-surface TF expression
showed that the number of TF-positive megakaryocytes
was significantly higher in hypertensive animals compared
with StD-WKY rats (Fig. 5b). It further increased in JpD-
SHRSP, in which hypertension is worsened by organ dam-
age. Of interest, the percentage of TF-positive megakar-
yocytes returned to the StD-SHRSP levels already after
1 week of treatment with captopril (Fig. 5b).
Effect of angiotensin on platelet tissue factor
expression
The activity of the renin–AngII system is increased in
SHRSP after high-salt diet treatment [15]. To evaluate the
effect of AngII on platelet activation in terms of surface-
associated TF expression, ex-vivo experiments on PRP from
normotensive StD-WKY rats were performed. Platelet stim-
ulation with a classical agonist, such as collagen (1 and
4mg/ml), was analyzed as positive control (Fig. 6a) and
resulted in a concentration-dependent increase in the num-
ber of surface-associated TF-positive platelets. Stimulation
with Val5AngII resulted in a concentration-dependent
increase in the number of TF-positive platelets compared
with untreated cells. Preincubation of platelets with valsar-
tan, a selective AT1 antagonist, inhibited TF upregulation
induced by AngII (Fig. 6b).
The effect of AngII on TF expression was evaluated also
in human platelets isolated from healthy individuals. Stim-
ulation of platelets with Val5AngII resulted in a concentra-
tion-dependent increase of the number of TF-positive
platelets (Fig. 6c), paralleling results obtained in animals.
DISCUSSION
The current study shows for the first time that the number of
TF-positive megakaryocytes and in turn the number of
FIGURE 4 (Continued)
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circulating platelets carrying a functionally active TF is
significantly increased in hypertensive compared with nor-
motensive status. This leads to a higher platelet prothrom-
botic potential as evidenced by a faster and greater
thrombin generation capacity, which is blunted by a spe-
cific anti-TF antibody. This picture is further exacerbated
when hypertension is complicated by end-organ damage
and endothelial cell dysfunction, which however can be
reverted by treatment with the AngII-converting enzyme
(ACE) inhibitor captopril.
Studies carried out in the past 15 years have documented
that TF, the transmembrane glycoprotein key activator of
the blood coagulation cascade and of thrombus formation,
is expressed not only by activated endothelial cells or
leukocytes, but also by circulating platelets of human, rat
and pig origin [24]. This finding has placed in a different
perspective the involvement of platelets in the thrombin
generation process, being their contribution not only in the
propagation of the clotting cascade, in which they provide
the negatively charged phospholipid bilayer for the assem-
bly of the coagulation factors, but also in the initiation
phase, being TF the trigger of the coagulation cascade.
TF is stored in the platelet cytoplasm and, upon activation
with classical agonists such as thrombin or ADP, it is rapidly
translocated on the cell surface in which it can bind factor
VIIa thereby leading to thrombin generation [5,25].
Platelets are generated by bone marrow resident mega-
karyocytes, a quite rare cell population, accounting for less
than 0.01% of the total cells present in the bone marrow,
which constantly release new platelets into the blood-
stream. We have recently shown that functionally active
TF is present in human megakaryoblasts and its expression
increases in megakaryocytes which then transfer it to a
subset of shed platelets in which it contributes to clot
formation. Although platelets do not have a nucleus, they
also contain, in addition to the protein, megakaryocyte-
derived TF pre-mRNA and mRNA that can be used, upon
activation, for de novo protein synthesis [6]. It is worth
mentioning, in this regard, that the TF mRNA species are
mostly stored in platelets containing a negligible amount of
TF protein. These TF mRNA-containing platelets can there-
fore become TF protein-containing platelets upon activa-
tion, as just mentioned above.
Of interest, the number of TF-positive platelets has been
previously shown to significantly increase in several path-
ological conditions, including diabetes and acute coronary
syndromes, compared with healthy status, providing an
additional explanation of the higher thrombogenicity
FIGURE 5 Analysis of cell-surface tissue factor expression in megakaryocytes by flow cytometry. Bone marrow megakaryocytes were identified by imaging flow cytometry
according to their physical properties and high CD61 expression. Cell nuclei were stained with DRAQ5 dye. Representative compensated images of standard diet (a1) and
Japanese high-salt permissive diet (a2) spontaneously hypertensive stroke prone megakaryocytes are reported in panel (a). Cell-surface tissue factor expression in mega-
karyocytes from Wistar Kyoto and spontaneously hypertensive stroke prone rats was quantified by traditional flow cytometry and reported as percentage of tissue factor-
positive cells (b). Lines in the dot plots are mean& SD. General linear models were applied for statistical analysis. P values were obtained by post-hoc tests with Bonferroni
correction.
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documented in these clinical settings [9,10]. The informa-
tion so far accumulated on the regulation of platelet TF do
not allow us to understand whether this increase is due to
mechanisms taking place in the bloodstream, ultimately
resulting in the translation of the platelet TF mRNAs, or in
the bone marrow, in which megakaryocytes could increase
the release of TF-positive platelets into the circulation. As
one can easily understand, this is an issue quite hard to be
solved in humans. Indeed, as far as the megakaryocytes are
concerned, their location being hardly accessible, together
with their low amount, definitely limits the possibility to
perform studies on mature megakaryocytes in humans.
Conversely, taking advantage from the SHRSP animal
model, we were able to gain further insights into these
mechanisms assessing TF expression in megakaryocytes by
flow cytometry. The data here reported clearly show that
hypertension is associated with a significant increase of the
number of TF-positive megakaryocytes, which in turn may
shed more TF-positive platelets in the circulation. In a
severe hypertensive status, such as that induced by the
administration of the high-salt diet and which is character-
ized by a severe renal impairment and endothelial dysfunc-
tion, the number of TF-positive megakaryocytes further
increases.
As the presence of TF in megakaryocytes has been only
recently characterized, data on its transcriptional regulation
in these cells are so far completely missing and will be
matter of future investigations. At present therefore we can
FIGURE 6 Flow cytometry analysis of cell-surface tissue factor expression in rat and human platelets stimulated with angiotensin II. Platelet-rich plasma from normotensive
Wistar Kyoto rats was stimulated with increasing concentration of collagen (a) or, a selective AT1 agonist (b), and stained with polyclonal antitissue factor antibody labeled
with Alexa Fluor 633. The effect of AngII on human platelets is also reported (c). Mean percentage of tissue factor-positive cells& SD, in each experimental setting, is
reported as histogram. ANOVA was applied for statistical analysis. P values were obtained by post-hoc test.
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only try to interpret our data borrowing the knowledge on
TF regulation learnt with other cells. The inducible expres-
sion of TF, which we believe is taking place in megakary-
ocytes in our experimental setting, is under the control of
the transcription factor NF-kB. This is activated, among the
others, by reactive oxygen species, inflammatory stimuli,
AngII (the effector arm of the renin–AngII system), all key
players in the vascular complications of hypertension [26–
28]. Indeed, consistent data in the literature have shown that
both inflammatory stimuli and AngII stimulate TF gene
transcription and expression in human monocytes, rat
aortic endothelial cells and vascular smooth muscle cells
[29–33]. As both inflammation and renin–AngII system are
increased in hypertensive SHRSP rats, especially when end-
organ damage and endothelial dysfunction are also present
[9,14,15,34,35], it is worth to speculate that they might affect
the TF gene transcription in megakaryocytes as well, but,
of course, this hypothesis has to be proved in future
investigations.
AngII is also able to activate platelets, increasing cyto-
solic-free calcium concentration and promoting both spon-
taneous and agonist-induced aggregation [35]. Thus, we
tested in ex-vivo experiments its effect on platelet TF
expression. Of interest, we found that stimulation of pla-
telets from normotensive rats with a Val5AngII resulted in a
rapid, concentration-dependent increase of cell-surface TF
expression. This effect was completely abolished by pre-
incubating platelets with valsartan, a selective AT1 antago-
nist, thus proving the specificity of the mechanism
involved. Of note, similar results were obtained also with
human platelets, suggesting that the same regulation may
take place also in humans.
As previously mentioned, however, prolonged platelet
activation results in mRNA translation and de novo protein
synthesis. As the activated renin–AngII system is more
pronounced in hypertension [36], platelets may be ‘chroni-
cally’ exposed to AngII. We cannot therefore rule out the
possibility that AngII may also exert its effect on platelet TF
expression through amechanism acting at the mRNA levels.
In the current study, we provided the evidence that,
when organ damage [37] and BP are controlled by captopril
treatment, the number of TF-positive megakaryocytes
returns to the basal levels, thus restoring also the number
of TF-positive platelets. As this effect was observed already
after 1 week of treatment, it is tempting to speculate that a
clear anti-inflammatory and antithrombotic properties of
the pharmacological renin–AngII system blockade, above
and beyond its antihypertensive properties, is taking place.
Indeed, it has been previously reported, that the pharma-
cological inhibition of the renin–AngII system by means of
drugs such as ACE inhibitors or AT1 blockers were able to
modulate TF in different cell types (reviewed in Celi et al.
[2]). We previously showed the capacity of captopril
to downregulate endotoxin-induced TF expression and
activity in human monocytes [38]. Valsartan was shown
to reduce TF expression in vascular cells such as endothe-
lium, smooth muscle cells and adventitia cells in transgenic
rat overexpressing human renin and angiotensinogen
genes [39].
Of note, this is not the first study suggesting the potential
involvement of platelet TF to thrombotic events. Our data
are indeed in line with a recent study by Tyagi et al. [12] who
reported, using a proteomic approach, that the exposure of
rats to a hypoxic stimulus results in the upregulation of
platelet TF expression and in the processing of the TF pre-
mRNA into mature RNA.
The contribution of TF to the prothrombotic phenotype
described in hypertension has been mainly linked to the
expression of the protein by activated monocytes and
endothelial cells. Nevertheless, data accumulated so far
on the characterization of platelet TF expression in healthy
as well as in pathological conditions indicate that the time
has come to consider activated platelets as a considerable
source of functionally active TF. In this regard, we have
previously reported that in patients with acute coronary
syndrome, although on a per-cell basis monocytes carry
more TF protein than platelets, the total amount of TF
carried by the platelets present in 1-ml blood volume far
exceed (1000-fold difference) the amount carried by mono-
cytes [28]. Finally, TF could be transferred from activated
platelets to monocytes and neutrophils through microves-
cicles, that are a considerable source of functionally active
TF and have a high procoagulant activity [40].
In our experimental setting, the hypertension did not
upregulate TF in monocytes and granulocytes. It is worth
mentioning in this regard that data reported in literature are
quite controversial. Although some studies clearly show that
AngII is able to increase in-vitro monocyte-TF expression
and activity [29,30], others suggest that hypertensive patients
without any other cardiovascular risk factors have levels of
monocyte-associatedTF comparable to that of normotensive
controls. The presence of additional risk factors, such as
carotid atherosclerosis, together with hypertension may sig-
nificantly influence TF levels in these cells [41].
In summary, our data suggest that new players, the TF-
expressing megakaryocytes and platelets, might contribute
to the well documented prothrombotic state observed in
the onset and evolution of a hypertensive status.
In addition, although the effect of the other players
involved in the end-organ damage and endothelial dys-
function could not be excluded, the renin–AngII system
may contribute to the procoagulant phenotype reported in
hypertensive animals. By ex-vivo experiments, we indeed
provided the direct evidence that AngII, through an AT1-
specific mechanism, induces the TF exposure on the plate-
let membrane, and this effect was observed also in human
platelets. Although data obtained with the animal model
need to be confirmed also in the clinical setting, it could be
anticipated that drugs interfering with the renin–AngII
system, in addition to lowering BP, may be beneficial for
preventing the increased thrombogenicity observed in
patients with hypertension.
Limitation of the study
The experimental setting used in the current study does not
allow to ascertain whether the modulation of TF expression
in megakaryocytes and platelets exerted by captopril is
related to changes in the renin–AngII system or to the
protective effect on the end-organ damage observed in
severe hypertensive animals. Indeed, inflammatory pro-
cesses as well as endothelial dysfunction taking place in
the SHRSP animal model may also contribute, in addition to
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the renin–AngII system activation, to the prothrombotic
phenotype of megakaryocytes and, in turn, of circulating
platelets. Further studies on animals treated with drugs able
to reduce BP without impacting AngII levels and/or the
extent of target organ damagewill help to unravel this issue.
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Reviewers’ Summary Evaluations
Reviewer 1
Strengths: The authors perform in vivo and in vitro assess-
ments to demonstrate that angiotensin II upregulates tissue
factor expression uniquely in platelets.
Weaknesses: Ultimately, the authors will need to deter-
mine the relationship between hypertension and/or target
organ damage and tissue factor expression.
Reviewer 2
The study by Brambilla et al. examined the effect of
captopril on cell-associated tissue factor (a key activator
of coagulation and thrombus formation) expression in
SHR-stroke prone rats fed either a standard of Japanese
high-salt permissive diet (i.e. altered sodium/potassium
ratio, low protein content, and 1% NaCl supplement in
the drinking water. SHR-stroke prone rats fed either a
normal or high-salt diet were found to have increased
platelet tissue factor expression in megakaryocytes) as
compared to WKY control rats. A high-salt diet exacer-
bated tissue factor expression in SHR-stroke prone rats
and was associated with a greater degree of hypertension
and renal injury compared to WKY control and SHR-
stroke prone rats fed a standard diet. A role for the
rennin–angiotensin system was implicated in these
responses, as captopril (an angiotensin-converting
enzyme inhibitor) was associated with a reduction in
the same end-points, including thrombin generation
assays. These findings demonstrate an association
between tissue factor expression in a genetic model of
hypertension and in response to a high-salt diet. The
observed increase in tissue factor in platelets may pro-
mote, in part, an increased risk of thrombotic events, such
as myocardial infarction, ischemic stroke, and renal
injury, commonly observed in hypertensive patients.
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